Man Hospitalized for Severe Hemoptysis Possibly Caused by E-cigarette

Regulations by 2FIRSTS.ai
Dec.14.2023
Man Hospitalized for Severe Hemoptysis Possibly Caused by E-cigarette
A man in Brasília has been hospitalized for a month due to severe coughing up blood symptoms believed to be caused by long-term e-cigarette use.

According to a report by Brazilian media outlet DM, a man has been hospitalized for a month in Brasília due to severe symptoms of hemoptysis, which is the presence of blood in coughed-up mucus. Doctors suspect that this condition may be a result of long-term use of e-cigarettes.

 

The man had been using e-cigarettes for the past three months, which is prohibited for sale in Brazil. However, a month ago, he started coughing up blood, making him realize the need for medical attention. In an interview with TV Globo, he stated, "Every day my symptoms were getting worse. I visited a private pulmonary doctor who conducted numerous tests but found no problems.

 

As a result, the doctor advised him to go home. However, his symptoms did not disappear, so he went to the emergency room at the North Wing Regional Hospital. He reported that one day he coughed up 600 milliliters of blood.

 

Since 2009, Brazil has implemented a regulation that prohibits the sale, import, and promotion of electronic vaping devices, including accessories and pods. The Brazilian National Health Surveillance Agency (Agência Nacional de Vigilância Sanitária) has launched a public consultation on December 12th to decide whether to lift the ban on e-cigarettes. The consultation will last until February 9th, providing 60 days for public participation.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

PMI says it submitted evidence to FDA panel backing ZYN bid for modified-risk status
PMI says it submitted evidence to FDA panel backing ZYN bid for modified-risk status
Philip Morris International said it presented scientific evidence to the U.S. Food and Drug Administration’s Tobacco Products Scientific Advisory Committee to support its ZYN nicotine pouches seeking a modified risk tobacco product designation, which would allow the company to communicate to adult smokers that switching completely to ZYN could reduce the risk of multiple smoking-related diseases.
Jan.26 by 2FIRSTS.ai
South Africa health department agrees to exempt smokeless and non-combustible products from tobacco control bill
South Africa health department agrees to exempt smokeless and non-combustible products from tobacco control bill
At a parliamentary committee meeting in South Africa, Health Minister Aaron Motsoaledi said the health department has agreed to exempt non-combustible and smokeless products — including chewing tobacco, snus, nicotine pouches and e-cigarettes — from the Tobacco Products and Electronic Delivery Systems Control Bill. The department is prepared, at this stage, to exempt them from packaging and labelling requirements except for misleading or false claims.
Mar.06 by 2FIRSTS.ai
Malaysian Langkawi marine police seize vape devices and e-liquid worth US$43,902
Malaysian Langkawi marine police seize vape devices and e-liquid worth US$43,902
In Langkawi, Malaysia, the Marine Police seized various vape devices and e-liquid valued at RM178,400 (about US$43,902.99). Authorities believe the goods were intended to be smuggled out to a neighboring country.
Jan.15 by 2FIRSTS.ai
Belarus plans to tighten licensing for e-cigarette and e-liquid trade; Lukashenko expresses support
Belarus plans to tighten licensing for e-cigarette and e-liquid trade; Lukashenko expresses support
A report says Belarus plans to tighten, at the legislative level, the licensing of trade in electronic cigarettes and related mixtures (e-liquids). The draft law was discussed at a meeting chaired by President Alexander Lukashenko with the leadership of the Council of Ministers, according to a BelTA correspondent.
Feb.06 by 2FIRSTS.ai
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
U.S.-based medical startup Qnovia Inc. reported positive results from its first-in-human clinical trial of RespiRx, an inhalable nicotine replacement therapy (NRT) device designed to support smoking cessation.
Innovation
Feb.24
Scientific talk in Bursa Nilüfer spotlights cigarette and e-cigarette addiction and youth risks
Scientific talk in Bursa Nilüfer spotlights cigarette and e-cigarette addiction and youth risks
Nilüfer Municipality in Bursa held a scientific talk titled “Does Addiction Change Form? Cigarettes, E-Cigarettes and Lung Health” as part of February 9 Quit Smoking Day, aiming to raise awareness of the social impact of tobacco addiction. Experts discussed cigarette and e-cigarette addiction, risks for young people, harms of secondhand smoke for children, and health outcomes linked to tobacco use.
Feb.10 by 2FIRSTS.ai